Our global patent estate includes over 220 issued or allowed patents owned or exclusively licensed by us and our Hong Kong subsidiary, Pangu BioPharma Limited. This patent estate highlights our unique leadership position in this emerging area of biology. Our achievements build on the important and innovative research from the laboratory of aTyr’s founders Dr. Paul Schimmel and Dr. Xiang-Lei Yang at The Scripps Research Institute, which continues to be a source of important innovation. These patents encompass important therapeutic modalities including composition of matter claims to the protein therapeutics, polynucleotide based therapeutics, antibodies and therapeutic methods of use. In addition to patent protection, we also rely on trade secrets and careful monitoring of our proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.
We also rely on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen, and maintain our proprietary position in the field of Physiocrine therapeutics.